publication date: May. 10, 2019

In Brief

Primo “Lucky” Lara now serves as SWOG deputy chair, Kathy Albain is vice president

Primo “Lucky” Lara was named deputy chair of SWOG Cancer Research Network and Kathy Albain now serves as vice chair of SWOG Cancer Research Network.

The appointments became effective March 1.

This role places Lara, director of the UC Davis Comprehensive Cancer Center, as second in command for SWOG, reporting to Group Chair Charles D. Blanke.

As deputy chair, Lara oversees all SWOG NCTN treatment trials and helps direct  the science, policy, operations, and strategic planning responsibilities for the group.

Lara brings a wealth of leadership experience to the role.

As head of the UC Davis Comprehensive Cancer Center, he oversees a team of more than 300 scientists with an estimated $90 million in annual research funding. The center sees an estimated 10,000 adult and pediatric patients each year.

Lara began his career at UC Davis as a hematology-oncology fellow and joined the faculty in 1999. A developmental therapeutics researcher, Lara served as the cancer center’s associate director for translational research and has led several phase I to phase III trials.

Lara may serve as SWOG deputy chair for as many as two six-year terms, or 12 years.

Albain, Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine, is leading the group’s Clinical Trials Partnerships, its initiative for collaborating with industry to conduct cancer clinical trials.

In this new position, Albain reports to SWOG Group Chair and provide scientific oversight for CTP, with special attention to preferred industry partnerships.

Albain is known for … Continue reading Primo “Lucky” Lara now serves as SWOG deputy chair, Kathy Albain is vice president

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.